IP Library Granted Patent US 10,603,364
Granted Patent B2
US 10,603,364 · App. 15/503,227 · Granted Mar 31, 2020

Lysosomal targeting and uses thereof

Inventors: Michael F. Concino (Lexington, MA); Bettina Strack-Logue (Lexington, MA); Muthuraman Meiyappan (Lexington, MA); Angela W. Norton (Lexington, MA); Bohong Zhang (Lexington, MA); Andrea Iskenderian (Lexington, MA); Jianwen Feng (Lexington, MA); Kevin Holmes (Lexington, MA); Jing Pan (Lexington, MA)
Assignee: Shire Human Genetic Therapies, Inc.
A61K38/47A61K47/64C07K14/475C07K14/70571C07K16/18C12N9/2402C12Y302/0105C07K2319/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,603,364
App. No.
15/503,227
Granted
Mar 31, 2020
Kind
B2
Abstract

The invention provides compositions and methods for effective lysosomal targeting mediated by SORT1. In particular, the compositions and methods provided by the invention may be used to treat lysosomal storage diseases such as Sanfilippo syndrome type B.

Claims (11)

1. A targeted fusion protein comprising:

a lysosomal enzyme; and

a lysosomal targeting moiety that comprises a Sortilin-1 receptor propeptide (SPP) comprising an amino acid sequence at least 95% identical to SEQ ID NO: 4.

2. The targeted fusion protein of claim 1 , wherein the lysosomal enzyme comprises an amino acid sequence identical to SEQ ID NO: 1.

3. The targeted fusion protein of claim 1 , wherein the SPP comprises SEQ ID NO:4.

4. The targeted fusion protein of claim 1 , wherein the lysosomal targeting moiety and the lysosomal enzyme are fused via a linker.

5. The targeted fusion protein of claim 4 , wherein the linker comprises a sequence of

GAPGGGGGAAAAAGGGGGGAPGGGGGAAAAAGGGGGGAPGGGGGAAAAA

GGGGGGAP,

6. The targeted fusion protein of claim 1 , wherein the targeted fusion protein comprises a sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 17.

7. The targeted fusion protein of claim 1 , wherein the targeted fusion protein comprises a sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 22.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2021
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056420/0964 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2017
From: CONCINO, MICHAEL F.; STRACK-LOGUE, BETTINA; MEIYAPPAN, MUTHURAMAN; NORTON, ANGELA W.; ZHANG, BOHONG; ISKENDERIAN, ANDREA; FENG, JIANWEN; HOLMES, KEVIN; PAN, JING
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 043145/0957 →